ACHN / ACHN-luc Orthotopic Mouse Model Service for Renal Cancer

The ACHN / ACHN-luc orthotopic mouse model for renal cancer is a human xenograft platform in which metastasis-derived ACHN renal adenocarcinoma cells are implanted into the kidney of immunodeficient mice, recreating organ-confined tumor growth within the native renal microenvironment together with spontaneous spread to the lung. Alfa Cytology provides this model as a fully managed preclinical capability — spanning authenticated ACHN / ACHN-luc expansion and luciferase-stable banking, precision intrarenal implantation, scheduled in vivo bioluminescence tracking of primary tumors and pulmonary lesions, and comprehensive necropsy histopathology — all configured to each sponsor’s agent, regimen, and endpoint plan.

Overview of ACHN / ACHN-luc Orthotopic Mouse Model for Renal Cancer

ACHN is among the oldest and most extensively characterized human renal cancer cell lines still in use, with a derivation history that makes it intrinsically a model of metastatic disease. The line was established in November 1979 from the malignant pleural effusion of a 22-year-old donor with widely metastatic renal cell adenocarcinoma (confirmed at autopsy), after the cells were seeded directly into culture and carried for 150 days before first passage into nude mice. Its histotype has been debated: early xenograft tumors were described as poorly differentiated clear cell carcinoma, whereas genomic and cytogenetic analyses — including a c-MET polymorphism characteristic of papillary renal cancer, gains of chromosomes 7 and 17, and 9p loss — point toward papillary features, while expression profiling shows clear cell-like behavior in the MYC pathway. Critically for experimental interpretation, ACHN carries no VHL mutation, consistent with its non-clear-cell character. The line is epithelial, G6PD type B, TP53 wild-type with detectable p53 protein, expresses carbonic anhydrase IX, and is growth-inhibited by human interferons — a property documented in both the original cells and cells recovered from mouse tumors.

Fig 1. In vivo BLI of 786-O-luc and ACHN-luc tumor burden (Empty vs SMOC2-overexpressing) at day 7, day 14 and endpoint, with total body luminescence quantification and ex vivo lung imaging. (Feng, Daniel, et al., 2022)

When grafted into its organ of origin, ACHN reproduces the behavior that made it famous: subcutaneous inoculation into nude mice yields locally invasive tumors within about four weeks (with 100% take at 1 × 10⁷ cells, appearing within 21 days), and intrarenal implantation converts this local invasiveness into a metastatic cascade that reaches the lung — the dominant clinical site of renal cancer dissemination. The ACHN-luc derivative, stably expressing firefly luciferase, quantifies every stage of that cascade non-invasively: primary renal tumor take and growth are followed by in vivo bioluminescence after luciferin administration, pulmonary metastatic seeding is flagged early by thoracic signal, and ex vivo organ imaging at necropsy confirms the metastatic map. Because the model has validated responsiveness to anti-angiogenic and targeted agents — including sunitinib in a left-ventricular bone metastasis setting, and the angiogenesis inhibitor TNP-470, which abolished lung metastasis from subcutaneous tumors — the ACHN / ACHN-luc orthotopic system supports angiogenesis research, VEGF/mTOR-pathway agent evaluation, interferon-response studies, and metastasis-biology work in a single, well-documented platform.

Cell Line Information: ACHN / ACHN-luc

The table below consolidates the key biological, cultural, and modeling characteristics of the ACHN parental line and its luciferase-labeled derivative ACHN-luc. Both are human-derived and require immunodeficient hosts for in vivo propagation.

Our Services

Operating the ACHN / ACHN-luc orthotopic model demands disciplined surgical technique and quantitative imaging discipline, and Alfa Cytology brings both: validated cell banks, subcapsular implantation into the left kidney with consistent take rates, weekly in vivo bioluminescence schedules, and metastasis-focused endpoint pathology — all delivered as one accountable preclinical program.

Workflow of ACHN / ACHN-luc Orthotopic Mouse Model Construction

Construction follows established intrarenal xenograft methodology: luciferase-labeled ACHN cells are expanded under authenticated conditions, formulated in a Matrigel-supported suspension, surgically implanted beneath the renal capsule or into the renal parenchyma of immunodeficient mice, and followed by serial imaging with metastasis-oriented endpoint analysis. The workflow comprises the following stages.

1. Cell authentication and banking: ACHN or ACHN-luc cells are verified by STR profiling, confirmed mycoplasma-free, and expanded into low-passage working banks under standardized EMEM culture conditions.
2. Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at the study-specified dose in the range of 1–5 × 10⁶ cells in 20–30 μL of serum-free medium mixed 1:1 with cold Matrigel and kept on ice until implantation.
3. Anesthesia and renal exposure: Male immunodeficient mice are anesthetized with isoflurane; a left flank incision opens the retroperitoneal space and gently exteriorizes the left kidney through a warm saline-moistened window.
4. Intrarenal implantation: The cell suspension is slowly injected beneath the renal capsule or into the parenchyma of the left kidney; the needle is held briefly after injection so the Matrigel partially sets, limiting reflux and ensuring uniform tumor take.
5. Closure and perioperative care: The kidney is returned to the retroperitoneum, muscle and skin layers are sutured, and animals receive analgesia with close post-operative monitoring until fully recovered.
6. Engraftment confirmation and serial imaging: Luciferin is administered intraperitoneally and bioluminescence is acquired to confirm renal tumor take and normalize group allocation; imaging repeats on a weekly cadence to track primary growth and flag emerging thoracic metastatic signal.
7. Intervention and endpoint analysis: Experimental arms — VEGF-pathway tyrosine kinase inhibitors, mTOR inhibitors, anti-angiogenic agents, interferon-based regimens, and combinations — proceed per study design; endpoints integrate imaging with tumor-bearing kidney weight, ex vivo lung bioluminescence and surface lesion counts, and histopathology (H&E with CD31, Ki67, and marker-specific immunohistochemistry).

Fig 2. ACHN / ACHN-luc orthotopic mouse model construction workflow.

Case Study-ACHN / ACHN-luc Orthotopic Mouse Model Development

Alfa Cytology has conducted preclinical programs on the ACHN / ACHN-luc orthotopic platform covering targeted-therapy evaluation, anti-angiogenesis research, and metastasis-biology investigation. In these studies, intrarenally implanted ACHN-luc tumors were longitudinally quantified by in vivo bioluminescence, with pulmonary metastatic burden assessed by ex vivo organ imaging and histopathological confirmation at endpoint. Program-specific datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology pairs seasoned renal-xenograft expertise with unified surgical, imaging, and pathology teams, so every ACHN / ACHN-luc orthotopic study is executed with reproducible technique and reporting that sponsors can stand behind.

• Demonstrated experience with intrarenal orthografts and metastasis-forward renal cancer study designs.
• A single integrated team managing cell banking, kidney implantation surgery, in vivo imaging, and endpoint pathology under one quality framework.
• Quantitative longitudinal bioluminescence readouts covering primary renal growth and early pulmonary metastatic emergence.
• Flexible regimens spanning VEGF, mTOR, anti-angiogenic, and interferon-based intervention arms.
• Clear milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your renal cancer program needs a rigorously controlled orthotopic platform with bioluminescent metastasis tracking, Alfa Cytology is ready to help. Reach out to us to discuss your agent, study design, and endpoint requirements, or contact us today for a customized proposal and quotation for the ACHN / ACHN-luc orthotopic mouse model service.

For research use only. Not intended for any clinical use.